scholarly journals Direct and Spillover Effects of Middle School Vaccination Requirements

2019 ◽  
Vol 11 (1) ◽  
pp. 95-125 ◽  
Author(s):  
Christopher S. Carpenter ◽  
Emily C. Lawler
Keyword(s):  
Middle School ◽  
Human Papillomavirus ◽  
Whooping Cough ◽  
Spillover Effects ◽  
School Entry ◽  
Low Ses ◽  
Vaccination Rates ◽  
Cervical Cancers ◽  
Tdap Vaccine ◽  
Adolescent Vaccination

We study the direct and spillover effects of state requirements that middle school youths obtain a tetanus, diphtheria, and pertussis (Tdap) booster prior to middle school entry. These mandates significantly increased Tdap vaccine take-up and reduced pertussis (whooping cough) incidence by about 32 percent. We also document cross-vaccine spillovers: the mandates significantly increased adolescent vaccination rates for meningococcal disease and human papillomavirus (HPV)—which is responsible for 98 percent of cervical cancers—by 8–34 percent, with particularly large effects for children from low SES households. We find important roles for both parents and providers in generating these spillovers. (JEL H75, I12, I18, I21, I28, J13)

The Intersection of Problems, Policy, and Politics: The Adoption of an HPV Vaccine School-Entry Requirement in Puerto Rico

2021 ◽  
Vol 31 (5) ◽  
pp. 859-870
Author(s):  
Coralia Vázquez-Otero ◽  
Ellen M. Daley ◽  
Cheryl A. Vamos ◽  
Nancy Romero-Daza ◽  
Jason Beckstead ◽  
...  
Keyword(s):  
Puerto Rico ◽  
Nonprofit Organizations ◽  
Hpv Vaccine ◽  
Hpv Vaccination ◽  
School Entry ◽  
Advisory Panel ◽  
Policy Entrepreneurs ◽  
Vaccination Rates ◽  
Policy Initiatives ◽  
Policy Window

Persistent human papillomavirus (HPV) infections can cause cancer (e.g., cervical/vaginal/penile/anal/oropharyngeal). The HPV vaccine prevents cancer, yet U.S. vaccination rates remain low. We explored sociopolitical factors in the adoption of Puerto Rico’s HPV vaccine school-entry requirement. Multiple streams framework explains how the intersection of problems, policy, and politics streams influence policy adoption. Policy entrepreneurs work on joining these streams. Interviews ( n = 20) were conducted with stakeholders (e.g., physicians/researchers/nonprofit organizations’ leaders). Data were analyzed using applied thematic analysis. High incidence of HPV and HPV-related cancers in Puerto Rico were indicators of problems. Focusing events included Rhaiza’s case and the HPV-Advisory Panel Report. During summer 2017, a policy window opened; the Department of Health (DOH) adopted the requirement in summer 2018. Stakeholders discussed policy initiatives. Political turnover positively influenced the process. Policy entrepreneurs created an extended period of intersection resulting in the adoption of the requirement. Findings can inform policy initiatives to improve HPV vaccination rates and reduce HPV-related cancers.

scholarly journals Human papillomavirus typing of invasive cervical cancers in Italy

2006 ◽  
Vol 1 (1) ◽  
Author(s):  
Annarosa Del Mistro ◽  
Helena Frayle Salamanca ◽  
Rossana Trevisan ◽  
Roberta Bertorelle ◽  
Anna Parenti ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Cancers

scholarly journals Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58

2014 ◽  
Vol 21 (4) ◽  
pp. 587-593 ◽  
Author(s):  
Martha J. Brown ◽  
Hanna Seitz ◽  
Victoria Towne ◽  
Martin Müller ◽  
Adam C. Finnefrock
Keyword(s):  
Monoclonal Antibodies ◽  
Human Papillomavirus ◽  
Immune Responses ◽  
Neutralizing Antibodies ◽  
Cervical Cancers ◽  
Hpv Types ◽  
Oncogenic Hpv ◽  
Neutralizing Epitopes ◽  
Selection Of

ABSTRACTHuman papillomavirus (HPV) is the etiological agent for all cervical cancers, a significant number of other anogenital cancers, and a growing number of head and neck cancers. Two licensed vaccines offer protection against the most prevalent oncogenic types, 16 and 18, responsible for approximately 70% of cervical cancer cases worldwide and one of these also offers protection against types 6 and 11, responsible for 90% of genital warts. The vaccines are comprised of recombinantly expressed major capsid proteins that self-assemble into virus-like particles (VLPs) and prevent infection by eliciting neutralizing antibodies. Adding the other frequently identified oncogenic types 31, 33, 45, 52, and 58 to a vaccine would increase the coverage against HPV-induced cancers to approximately 90%. We describe the generation and characterization of panels of monoclonal antibodies to these five additional oncogenic HPV types, and the selection of antibody pairs that were high affinity and type specific and recognized conformation-dependent neutralizing epitopes. Such characteristics make these antibodies useful tools for monitoring the production and potency of a prototype vaccine as well as monitoring vaccine-induced immune responses in the clinic.

Genomic Aberrations of Human Papillomavirus Recovered from Cervical Cancers

1996 ◽  
Vol 222 (1) ◽  
pp. 116-120 ◽  
Author(s):  
Chia C. Pao ◽  
Ding-Shyan Yao ◽  
Chieh-Yu Lin ◽  
Shih Ching Lee ◽  
Ho Ting Su ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cervical Cancers ◽  
Genomic Aberrations

Pertussis

2021 ◽  
Author(s):  
Carl Heinz Wirsing von König
Keyword(s):  
Whooping Cough ◽  
Severe Disease ◽  
Newborn Infants ◽  
School Entry ◽  
Whole Cell ◽  
Young Infants ◽  
Combination Vaccines ◽  
Adolescents And Adults ◽  
Second Year ◽  
Acellular Vaccines

The bacterium Bordetella pertussis causes disease by producing various virulence and adhesion factors, among them pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and agglutinogens (Agg), also called fimbriae (FIM) "Typical" pertussis or whooping cough starts with unspecific respiratory symptoms (catarrhal phase) followed by severe coughing spasms with whoops and vomiting (paroxysmal phase) and only after weeks or months disease severity slowly wanes (convalescent phase). "Atypical pertussis" with unspecific, long-lasting coughing episodes is seen in adolescents and adults; very young infants may die from apnoea. B. pertussis is transmitted by droplets, and neither infection nor vaccination produce long lasting protection. Macrolide antibiotics are given to patients and their contacts to reduce spread of the organism; however, antibiotics do NOT change the duration or course of the disease once symptoms are present. Whole cell pertussis vaccines (wP) consist of whole inactivated B. pertussis-cells, whereas acellular vaccines (aP) consist of one to five single components like PT, FHA, PRN or FIM. Pertussis vaccines are currently only available as combination vaccines with tetanus und diphtheria (DTP). Among these are DTwP; DTaP; TdaP; and various DTP-combinations with Hib, IPV, HBV vaccines. Whole cell pertussis (DTwP) combination vaccines are more reactogenic, whereas DTaP vaccines are generally well tolerated. Some DTwP had good efficacy/effectiveness (90%), it was low (40%) with others. Vaccine efficacy of DTaP vaccines ranges between 70% and 90%. As with most vaccines, efficiency is higher for severe disease. While pertussis vaccines did control clinical disease, protection is limited. Vaccination is recommended for all infants (three doses) worldwide with a booster in the second year of life. Many countries give additional doses at school entry and in adolescents, and some to adults. Vaccination of pregnant women effectively protects newborn infants and is increasingly recommended.

Sign in / Sign up

Export Citation Format

Share Document